For examples, administration of APLs of a known immunodominant CD8+ T cell epitope with partial agonist activity (12) or nanoparticles coated with APL-MHCs complexes (13) has been shown to effectively induce autoreactive CD8+ T cell tolerance and prevent T1D in NOD mice. Here, CD8A is linked to type 1 diabetes mellitus.